To understand whether liver specific effects of TIMP3/ADAM17 play a role in modulating steatosis onset independently from other broad systemic effects on immune system and other tissues, we have generated transgenic mice overexpressing TIMP3 specifically in the liver (AlbT3), as well as hepatocyte specific ADAM17 knockout mice (A17LKO) or myeloid lineage-specific ADAM17 knockout mice (A17MKO). Here, TIMP3 is linked to steatosis.